Use our account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
Use our account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

This field is for validation purposes and should be left unchanged.

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Abortion Drugs

Texas Lawsuit Seeks to Take at-Home Abortion Pills Off the Market Nationwide

Both sides of the abortion issue are waiting for a federal judge in Texas to rule on a lawsuit that could force the FDA to withdraw chemical abortion pills from the market.

This case follows the FDA’s decision to expand access to the two-part drug regimen, allowing doctors to prescribe it via telehealth appointments for women to receive the abortion-inducing pills through the mail.

The Texas lawsuit claims mifepristone, the first of the two drugs taken to induce abortion, is not as safe as advertised and should not have received FDA approval back in 2000.

These chemical procedures currently account for more than 50% of all abortions in the United States. For many years, the FDA sought to expand access to the two-part at-home pill regimen even though a number of doctors and medical organizations question its safety and its approval more than two decades ago.

“From approval and then every time the FDA has loosened its restrictions, it has gone against its own rules to do so,” Dr. Ingrid Skop from the Charlotte Lozier Institute told CBN News.

Dr. Skop says it was initially approved under a category called “subpart h” which is for drugs that treat life-threatening illnesses…

Continue Reading at CBN >>

Latest Posts

January 13, 2025 Supporting Mothers, Strengthening Futures: Reforming Tennessee’s Policies for Families with Young Children January 13, 2025 Filed: CLI and ACLJ Amicus Brief in SisterSong v. Georgia January 10, 2025 Abortion Reporting: Arizona (2023)

You Might Also Be Interested In

Fact Sheet: Questions and Answers on Born-Alive Abortion Survivors

charlotte-lozier-institute Charlotte Lozier Institute
December 19, 2024
Please login to bookmark Close
Fact Sheet: A Summary of the CDC’s 2022 Abortion Surveillance Report

Fact Sheet: A Summary of the CDC’s 2022 Abortion Surveillance Report

December 18, 2024
Please login to bookmark Close

Abortion Reporting: Massachusetts (2023)

November 27, 2024
Please login to bookmark Close

Become A Defender of Life

Your donation helps us continue to provide
world-class research in defense of life.

BECOME A PARTNER
cta-image